Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

NCT01412944 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque-type Psoriasis

Interventions

DRUG: secukinumab 150mg
DRUG: secukinumab 10mg/kg i.v. regimen

Sponsor

Novartis Pharmaceuticals